Clinical Trials Directory

Trials / Unknown

UnknownNCT02878278

Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect,Pharmacokinetics, Pharmacodynamics and EB Virus Activation

Research About the Differences Between Chidamide Taken Daily and Twice a Week in Pharmacokinetics

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
24 (estimated)
Sponsor
Huiqiang Huang · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

1. To compare the therapeutic effects, safety and the corresponding pharmacokinetics and pharmacodynamics between two different method of drug administration: 10mg, daily and 30mg/d, twice every week, and find out the more effect way of Chidamide administration. 2. To examine whether Chidamide could activate EB virus, and whether the above two different ways of administration are different in EB virus activation.

Detailed description

Currently, Chidamide is taken twice a week, this comes from cell experiment and phase I clinical trial, which showed that the de-acetylation effect of Chidamide could last for 72 hours after administration. However, daily administration of Chidamide may create a more steady Chidamide concentration, thus improve the de-acetylation effect of Chidamide, so it's necessary to compare the two different ways of administration. Current study showed that Romidepsin, a HDACI, could activate EBV during the treatment of NKTCL, whether Chidamide, as a novel HDACI, could activate EBV is still not clear, so this problem is worth to be accessed.

Conditions

Interventions

TypeNameDescription
DRUGChidamide BIWChidamide is given 30mg, twice a week
DRUGChidamide QDChidamide is given 10mg,QD

Timeline

Start date
2016-09-01
Primary completion
2019-03-01
Completion
2019-09-01
First posted
2016-08-25
Last updated
2016-08-25

Source: ClinicalTrials.gov record NCT02878278. Inclusion in this directory is not an endorsement.